Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › cardiopulmonary bypass

Cardiopulmonary bypass

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for cardiopulmonary bypass

15 trials tracked for cardiopulmonary bypass: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 1 citation.

15Trials tracked
6Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 3 Phase 2 4 Other / NA 5
  1. Phase 3 Colloids in Pediatric Cardiac Surgery: Comparison Between a Balanced and a Non-balanced Colloid Completed · 1 cited
  2. Phase 4 Platelet Transfusion During Neonatal Open Heart Surgery Completed
  3. Phase 4 Voluven® in Paediatric Patients Completed
  4. Phase 4 The RAS, Fibrinolysis and Cardiopulmonary Bypass Completed
  5. Phase 3 Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF Completed
  6. Phase 3 Bradykinin Receptor Antagonism During Cardiopulmonary Bypass Completed
Show 9 more trials
  1. Phase 2 Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass Completed
  2. Phase 2 Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery Completed
  3. Phase 2 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery Completed
  4. Phase 2 Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Completed
  5. N/A Cerebral Autoregulation Monitoring During Cardiac Surgery Completed
  6. N/A Point of Care Testing in Pediatric Patients Undergoing Major Surgery Completed
  7. N/A Hemosonics- VCU Cardiac Surgery Clinical Study Completed
  8. N/A Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery Completed
  9. N/A Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Cardiopulmonary bypass: what the trials found

Several trials evaluated various pharmacological and procedural interventions for managing clinical outcomes in surgical and critical care settings. In a study of platelet transfusion, patients showed no mortality at 30 days 1. A trial involving HOE 140 demonstrated no significant differences between groups regarding allogenic blood product transfusion risk, units of packed red blood cells transfused, or units of plasma transfused during hospitalization 6.

In a study evaluating L-alanyl-L-glutamine dipeptide, there was no significant difference in Plasma Troponin I levels at baseline or 5 minutes after cardiopulmonary bypass; however, a statistically significant difference was observed at 6 hours post-cardiopulmonary bypass (p=0.034) 5.

Recent results — preliminary, needs further review

  • Normoxia with controlled re-oxygenation showed significantly lower systemic oxidative stress based on TBARS compared to the control group (p=<0.01), though no significant differences were found in postoperative length of stay or days alive and out of the ICU at 30 days 11. While not yet corroborated, several trials investigated experimental interventions: AT-III 7, Periostat 8, MDCO-2010 9, Phenoxybenzamine 10, blood pressure maintenance based on cerebral blood flow autoregulation 12, Tranexamic Acid 13, Coagulation function 14, and CoaguChek 15.

For the clinician treating this condition

  • Platelet transfusion was associated with zero 30-day mortality in the studied cohort 1.
  • HOE 140 did not significantly impact the volume of red blood cells or plasma transfusions required during hospitalization 6.
  • L-alanyl-L-glutamine dipeptide showed a significant difference in Troponin I levels specifically at the 6-hour mark post-cardiopulmonary bypass 5.

AI synthesis of 12 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Low-tidal volume ventilation during cardiopulmonary bypass associates with higher mechanical power in patients developing postoperative pulmonary complications
Cardiology Cohort
Low-tidal volume ventilation during cardiopulmonary bypass associates with higher mechanical power in patients developing postoperative pulmonary complications Low-tidal volume ventilation linked to higher power during heart surgery
This prospective observational study evaluated patients undergoing cardiac surgery requiring cardiopulmonary bypass.
Patients with lung complications after heart surgery showed higher mechanical power when ventilation continued during bypass compared to tho…
Frontiers Apr 30, 2026
Ceftaroline fosamil pharmacokinetics during cardiac surgery with cardiopulmonary bypass
Drug Pipeline Cohort
Ceftaroline fosamil pharmacokinetics during cardiac surgery with cardiopulmonary bypass Ceftaroline Penetration in Heart Surgery Is Surprisingly Unpredictable
This prospective, randomized pharmacokinetic study in 14 patients undergoing cardiac surgery with cardiopulmonary bypass compared intermitte…
High blood levels of this antibiotic do not guarantee it reaches the infection site under the skin after heart surgery.
Frontiers Apr 24, 2026